U.S. Venture Partners

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed a Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical challenge of reliable fixation for glenoid implants. This technology not only enhances post-surgical implant stability, reducing the risk of revision surgeries, but also simplifies surgical instrumentation, which can lead to shorter operative times and lower costs. Shoulder Innovations markets its products through distribution partners across the United States, aiming to improve patient care and reduce overall healthcare costs.

Nervonik is a medical device company specializing in the development of an opioid-free peripheral nerve stimulation system. The company focuses on advancing its clinical research and achieving regulatory approvals for its innovative neuro-modulation device, which is designed for therapeutic applications. This miniaturized device employs sensing feedback to deliver closed-loop optimized therapy, allowing patients to receive targeted treatment for chronic disorders. Through its commitment to innovation, Nervonik aims to provide effective alternatives for pain management without reliance on opioids.

Okami Medical, Inc. is a manufacturer of medical devices specializing in the occlusion of peripheral vessels, primarily through its innovative LOw-profile Braided Occluder (LOBO) system. This device provides interventional physicians with a single solution for occluding various arterial targets, eliminating the need for multiple embolic devices. The LOBO incorporates proprietary HDBRAID technology, which features a unique pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011 and headquartered in Aliso Viejo, California, Okami Medical was established to meet the evolving needs of patients and healthcare providers by developing versatile and intuitive devices that ensure rapid and reliable vessel occlusion under diverse conditions.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke management.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Cagent Vascular, LLC is a medical device company based in Wayne, Pennsylvania, focused on developing innovative solutions for cardiovascular diseases. The company specializes in angioplasty balloons that utilize proprietary serration technology to enhance treatment outcomes. Its flagship product, the Serranator, features serrated metal strips embedded in a semi-compliant balloon, designed specifically for the treatment of atherosclerosis and conditions such as peripheral artery disease and chronic limb-threatening ischemia. By employing a minimally invasive approach, Cagent Vascular aims to improve vessel dilatation during cardiovascular interventions, ultimately enhancing patient care and quality of life. Founded in 2014, the company is dedicated to advancing intravascular technology in the medical field.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke management.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed a Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical challenge of reliable fixation for glenoid implants. This technology not only enhances post-surgical implant stability, reducing the risk of revision surgeries, but also simplifies surgical instrumentation, which can lead to shorter operative times and lower costs. Shoulder Innovations markets its products through distribution partners across the United States, aiming to improve patient care and reduce overall healthcare costs.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke management.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed a Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical challenge of reliable fixation for glenoid implants. This technology not only enhances post-surgical implant stability, reducing the risk of revision surgeries, but also simplifies surgical instrumentation, which can lead to shorter operative times and lower costs. Shoulder Innovations markets its products through distribution partners across the United States, aiming to improve patient care and reduce overall healthcare costs.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Medigate by Claroty is a developer of a medical device security platform that safeguards healthcare provider networks from cyber threats. Founded in 2017, the company is headquartered in New York City and focuses on protecting all connected medical devices within these networks. Its platform utilizes deep packet inspection to decode proprietary healthcare IoT protocols, providing visibility and security for IoT and medical devices. By offering threat detection and attack prevention services, Medigate enhances the safety and privacy of hospital environments, allowing for the secure deployment of both existing and new medical devices.

Optimize Health is a digital healthcare provider specializing in remote patient monitoring (RPM) solutions. The company offers a user-friendly platform that incorporates both equipment and software designed to streamline the implementation of RPM programs. Its software aids healthcare providers in complying with Medicare billing requirements for RPM services while ensuring a positive experience for both patients and providers. The platform automatically tracks medication doses and sends reminders to users, leveraging Bluetooth technology to sync with smartphones and tablets. This approach empowers patients to manage their health effectively and enables physicians to achieve profitability from RPM services starting in the first month.

Okami Medical, Inc. is a manufacturer of medical devices specializing in the occlusion of peripheral vessels, primarily through its innovative LOw-profile Braided Occluder (LOBO) system. This device provides interventional physicians with a single solution for occluding various arterial targets, eliminating the need for multiple embolic devices. The LOBO incorporates proprietary HDBRAID technology, which features a unique pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011 and headquartered in Aliso Viejo, California, Okami Medical was established to meet the evolving needs of patients and healthcare providers by developing versatile and intuitive devices that ensure rapid and reliable vessel occlusion under diverse conditions.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Medigate by Claroty is a developer of a medical device security platform that safeguards healthcare provider networks from cyber threats. Founded in 2017, the company is headquartered in New York City and focuses on protecting all connected medical devices within these networks. Its platform utilizes deep packet inspection to decode proprietary healthcare IoT protocols, providing visibility and security for IoT and medical devices. By offering threat detection and attack prevention services, Medigate enhances the safety and privacy of hospital environments, allowing for the secure deployment of both existing and new medical devices.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.

Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke management.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Neoconix, Inc. is a supplier of low-profile, high-performance electrical connectors tailored for mobile, enterprise IT, and industrial markets. Established in 2002 and based in San Jose, California, the company specializes in miniaturized connector solutions, utilizing its patented PCBeam technology to ensure rapid development and competitive pricing. Neoconix offers a diverse range of products, including standard mobile connectors, high-speed connectors, custom solutions like battery and display connectors, and various assemblies such as the FPConnected family. Its products serve multiple sectors, including computing, telecommunications, consumer electronics, military-aerospace, medical, and test equipment markets. With over 60 patents issued or pending, Neoconix is recognized for delivering industry-leading reliability and performance, achieving speeds exceeding 25Gb/s for various applications.

NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, founded in 2006. The company specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Its innovative system is designed to accommodate a range of vessel diameters, from small vessels at the ankle to larger vessels above the knee, thereby enhancing treatment options for patients suffering from this condition.

ApniCure, Inc. is a medical device company based in Redwood City, California, founded in 2005. The company specializes in developing and commercializing innovative home-use devices that utilize a proprietary technology known as Oral Pressure Therapy (OPT) to treat obstructive sleep apnea (OSA) and other sleep-related disorders. ApniCure has received FDA clearance to market its Winx® Sleep Therapy System in the United States, allowing patients to use this system at home to manage their condition. The company is committed to enhancing the quality of life for individuals affected by sleep disordered breathing through effective and accessible sleep therapy solutions.

Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.

NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.

Articulinx, Inc. is a medical device company based in Cupertino, California, specializing in the manufacture of implants and devices for the treatment of hand osteoarthritis. Founded in 2007, the company focuses on providing minimally-invasive solutions that restore joint mobility and alleviate joint pain, thereby reducing the need for surgeries. Its products cater to the orthopedic, extremities, and small joints markets in the United States, aiming to improve patient outcomes and enhance quality of life for those suffering from hand osteoarthritis.

Neoconix, Inc. is a supplier of low-profile, high-performance electrical connectors tailored for mobile, enterprise IT, and industrial markets. Established in 2002 and based in San Jose, California, the company specializes in miniaturized connector solutions, utilizing its patented PCBeam technology to ensure rapid development and competitive pricing. Neoconix offers a diverse range of products, including standard mobile connectors, high-speed connectors, custom solutions like battery and display connectors, and various assemblies such as the FPConnected family. Its products serve multiple sectors, including computing, telecommunications, consumer electronics, military-aerospace, medical, and test equipment markets. With over 60 patents issued or pending, Neoconix is recognized for delivering industry-leading reliability and performance, achieving speeds exceeding 25Gb/s for various applications.

Aptus Endosystems, Inc. is a medical device company focused on developing innovative solutions for endovascular aneurysm repair (EVAR). Founded in 2002 and based in Sunnyvale, California, the company specializes in advanced technologies for treating aortic aneurysm disease. Its flagship products include the Heli-FX EndoAnchor system, designed for abdominal and thoracic aortic aneurysms, and the Aptus TourGuide steerable sheath, which facilitates the delivery of peripheral vascular products. The proprietary helical staple technology used in the endograft system allows for independent fixation, mimicking suturing in open surgical procedures while maintaining a minimally invasive approach. Aptus Endosystems serves a range of markets, including the United States and several European countries, distributing its products through various distributors. The company's products hold CE Marking for distribution in the European Union, although they are currently designated for investigational use only in the United States.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, founded in 2006. The company specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Its innovative system is designed to accommodate a range of vessel diameters, from small vessels at the ankle to larger vessels above the knee, thereby enhancing treatment options for patients suffering from this condition.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.

Aptus Endosystems, Inc. is a medical device company focused on developing innovative solutions for endovascular aneurysm repair (EVAR). Founded in 2002 and based in Sunnyvale, California, the company specializes in advanced technologies for treating aortic aneurysm disease. Its flagship products include the Heli-FX EndoAnchor system, designed for abdominal and thoracic aortic aneurysms, and the Aptus TourGuide steerable sheath, which facilitates the delivery of peripheral vascular products. The proprietary helical staple technology used in the endograft system allows for independent fixation, mimicking suturing in open surgical procedures while maintaining a minimally invasive approach. Aptus Endosystems serves a range of markets, including the United States and several European countries, distributing its products through various distributors. The company's products hold CE Marking for distribution in the European Union, although they are currently designated for investigational use only in the United States.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Articulinx, Inc. is a medical device company based in Cupertino, California, specializing in the manufacture of implants and devices for the treatment of hand osteoarthritis. Founded in 2007, the company focuses on providing minimally-invasive solutions that restore joint mobility and alleviate joint pain, thereby reducing the need for surgeries. Its products cater to the orthopedic, extremities, and small joints markets in the United States, aiming to improve patient outcomes and enhance quality of life for those suffering from hand osteoarthritis.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.

Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, founded in 2006. The company specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Its innovative system is designed to accommodate a range of vessel diameters, from small vessels at the ankle to larger vessels above the knee, thereby enhancing treatment options for patients suffering from this condition.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Optichron, Inc. specializes in nonlinear signal processing technology, designing and manufacturing integrated circuits that enhance cost and performance in communications applications. Founded in January 2003, the company addresses the challenge of nonlinear distortion, a significant barrier in signal processing across various industries. This distortion hinders optimal performance in areas such as communications and data conversion. Optichron's team has developed a proprietary mathematical approach that underpins a robust integrated circuit architecture, forming the basis of its linearization products. By effectively mitigating nonlinear distortion, the company's technology improves overall system design parameters, resulting in reduced component counts and improved efficiency, ultimately lowering costs and power consumption. Optichron's products find applications in diverse fields, including wireless communications, software-defined radio, medical imaging, satellite communications, radar, infrared imaging, and test and measurement instrumentation, supported by a digital pre-distortion development tool suite for design migration across multiple protocols.

Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.

Neoconix, Inc. is a supplier of low-profile, high-performance electrical connectors tailored for mobile, enterprise IT, and industrial markets. Established in 2002 and based in San Jose, California, the company specializes in miniaturized connector solutions, utilizing its patented PCBeam technology to ensure rapid development and competitive pricing. Neoconix offers a diverse range of products, including standard mobile connectors, high-speed connectors, custom solutions like battery and display connectors, and various assemblies such as the FPConnected family. Its products serve multiple sectors, including computing, telecommunications, consumer electronics, military-aerospace, medical, and test equipment markets. With over 60 patents issued or pending, Neoconix is recognized for delivering industry-leading reliability and performance, achieving speeds exceeding 25Gb/s for various applications.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

CritiSense, Ltd. is a medical technology company that specializes in the real-time monitoring of patients' metabolic states, particularly during surgical procedures and in intensive care units. Founded in 2004 and based in Giv'at Shmu'el, Israel, the company has developed the CritiView, a sophisticated monitoring system that provides continuous, real-time data through the assessment of four physiological parameters at the tissue level. This device enables healthcare professionals, including surgeons, anesthesiologists, and ICU caregivers, to identify imbalances in tissue and body vitality by monitoring mitochondrial function, microcirculatory blood flow, and oxygen saturation. The technology, rooted in the expertise of co-founder Professor Avraham Mayevsky, enhances surgical outcomes and patient care by facilitating informed clinical decisions based on comprehensive physiological insights.

Neoconix, Inc. is a supplier of low-profile, high-performance electrical connectors tailored for mobile, enterprise IT, and industrial markets. Established in 2002 and based in San Jose, California, the company specializes in miniaturized connector solutions, utilizing its patented PCBeam technology to ensure rapid development and competitive pricing. Neoconix offers a diverse range of products, including standard mobile connectors, high-speed connectors, custom solutions like battery and display connectors, and various assemblies such as the FPConnected family. Its products serve multiple sectors, including computing, telecommunications, consumer electronics, military-aerospace, medical, and test equipment markets. With over 60 patents issued or pending, Neoconix is recognized for delivering industry-leading reliability and performance, achieving speeds exceeding 25Gb/s for various applications.

Neoconix, Inc. is a supplier of low-profile, high-performance electrical connectors tailored for mobile, enterprise IT, and industrial markets. Established in 2002 and based in San Jose, California, the company specializes in miniaturized connector solutions, utilizing its patented PCBeam technology to ensure rapid development and competitive pricing. Neoconix offers a diverse range of products, including standard mobile connectors, high-speed connectors, custom solutions like battery and display connectors, and various assemblies such as the FPConnected family. Its products serve multiple sectors, including computing, telecommunications, consumer electronics, military-aerospace, medical, and test equipment markets. With over 60 patents issued or pending, Neoconix is recognized for delivering industry-leading reliability and performance, achieving speeds exceeding 25Gb/s for various applications.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

Optichron, Inc. specializes in nonlinear signal processing technology, designing and manufacturing integrated circuits that enhance cost and performance in communications applications. Founded in January 2003, the company addresses the challenge of nonlinear distortion, a significant barrier in signal processing across various industries. This distortion hinders optimal performance in areas such as communications and data conversion. Optichron's team has developed a proprietary mathematical approach that underpins a robust integrated circuit architecture, forming the basis of its linearization products. By effectively mitigating nonlinear distortion, the company's technology improves overall system design parameters, resulting in reduced component counts and improved efficiency, ultimately lowering costs and power consumption. Optichron's products find applications in diverse fields, including wireless communications, software-defined radio, medical imaging, satellite communications, radar, infrared imaging, and test and measurement instrumentation, supported by a digital pre-distortion development tool suite for design migration across multiple protocols.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, which includes a comprehensive suite of assays for assessing platelet function. Founded in 1996, the company initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. Accumetrics focuses on diagnostic instrumentation and test kits designed to measure individual responses to various antiplatelet agents, providing essential tools for healthcare professionals in the evaluation of platelet activity and ensuring effective patient treatment.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

MicroVention Terumo is a medical device company specializing in catheter-based and minimally-invasive technologies for treating cerebral aneurysms and other neurovascular conditions. Founded in 1997 and headquartered in Tustin, California, the company develops a range of products, including delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters. Its notable technologies include the HydroCoil Embolic System, which utilizes platinum micro-coil technology for endovascular embolization, and the MicroPlex Coil System, designed for various aneurysm morphologies. MicroVention Terumo distributes its products through a network of specialty distributors across North America, South America, Europe, Africa, the Middle East, and Asia Pacific. The company has been operating as a subsidiary of Terumo Corporation since 2006.

AtriCure, Inc. is a medical device company specializing in the development, manufacture, and sale of surgical devices for the ablation of cardiac tissue. Founded in 2000 and headquartered in Mason, Ohio, AtriCure's product offerings include the Isolator Synergy and Isolator Synergy Access clamps for treating persistent atrial fibrillation, the EPi-Sense guided coagulation system, and the COBRA Fusion surgical ablation system. The company also provides multifunctional tools for cardiac evaluation and ablation, cryoablation systems, and instruments for cardiac surgeries. Its innovative solutions are designed to support minimally invasive cardiac and thoracic surgeries, addressing various conditions such as atrial fibrillation and postoperative pain management. AtriCure distributes its products through a combination of independent distributors and direct sales personnel, primarily focusing on the U.S. market.

Healinx is a unique medical relationship management application service provider (ASP). Our mission is to increase communication and the satisfaction level between patients and their doctors, while enhancing physician practice efficiency and profitability. By providing a Web-based channel that links patients directly to their personal doctors, Healinx allows patients to communicate with their doctors or access their medical information anytime -- from anywhere. In addition, patients can receive personalized health information from their doctors. The Healinx customized Internet messaging enables doctors and patients to communicate online with state of the art security and privacy. In addition, the Healinx channel includes a set of tools for electronic prescriptions and preventive care.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

AtriCure, Inc. is a medical device company specializing in the development, manufacture, and sale of surgical devices for the ablation of cardiac tissue. Founded in 2000 and headquartered in Mason, Ohio, AtriCure's product offerings include the Isolator Synergy and Isolator Synergy Access clamps for treating persistent atrial fibrillation, the EPi-Sense guided coagulation system, and the COBRA Fusion surgical ablation system. The company also provides multifunctional tools for cardiac evaluation and ablation, cryoablation systems, and instruments for cardiac surgeries. Its innovative solutions are designed to support minimally invasive cardiac and thoracic surgeries, addressing various conditions such as atrial fibrillation and postoperative pain management. AtriCure distributes its products through a combination of independent distributors and direct sales personnel, primarily focusing on the U.S. market.

Healinx is a unique medical relationship management application service provider (ASP). Our mission is to increase communication and the satisfaction level between patients and their doctors, while enhancing physician practice efficiency and profitability. By providing a Web-based channel that links patients directly to their personal doctors, Healinx allows patients to communicate with their doctors or access their medical information anytime -- from anywhere. In addition, patients can receive personalized health information from their doctors. The Healinx customized Internet messaging enables doctors and patients to communicate online with state of the art security and privacy. In addition, the Healinx channel includes a set of tools for electronic prescriptions and preventive care.

St. Francis Medical Technologies is a privately held company that manufactures the X-Stop interspinous process decompression system. The X-Stop implant is the first FDA-approved interspinous process device indicated for treating lumbar spinal stenosis.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.